Human breast milk extracellular vesicles from mothers with asthma differentially modulate the release of inflammatory cytokines by primary human airway smooth muscle cells in a recipient-cell specific manner

Breast milk extracellular vesicles from mothers with asthma exhibit distinct biophysical properties and differentially modulate inflammatory cytokine release in primary human airway smooth muscle cells depending on the specific asthma status of both the maternal donor and the recipient cell.

The Gist

The Big Picture: Breast Milk as a "Smart Delivery Service"

Imagine breast milk isn't just food; it's a high-tech delivery service. Inside every drop of milk are tiny, microscopic packages called Extracellular Vesicles (EVs). Think of these EVs as "envelopes" or "drones" that carry important instructions (cargo like proteins and genetic code) from the mother to the baby.

Usually, we think of these envelopes going to the baby's stomach to help with digestion. But this study asks a fascinating question: What if these envelopes also fly up into the baby's lungs?

The researchers wanted to know if the "instructions" inside these envelopes change depending on whether the mother has asthma. Do mothers with asthma send different "drones" than healthy mothers? And if those drones land on the baby's lung cells, do they tell the lungs to calm down or to get angry?

---

The Experiment: A "Lung Cell" Test Kitchen

To find out, the scientists set up a little test kitchen in a lab:

1. The Ingredients: They collected breast milk from two groups of moms: 5 moms with asthma and 5 moms without asthma.
2. The Test Subjects: They used human lung muscle cells (the cells that control how tight or loose your airways are). They had two types of these cells:
   • Control Cells: From people who never had asthma.
   • Asthma Cells: From people who do have asthma.
3. The Mix: They took the "drones" (EVs) from the moms' milk and dropped them onto the lung cells to see what happened.

---

The Findings: Different Moms, Different Packages

Here is what they discovered, broken down simply:

1. The Asthma Moms Sent More Drones, but Smaller Ones

The moms with asthma were sending out a much larger volume of these microscopic envelopes—about 5 times more than the healthy moms. However, the envelopes from the asthma moms were slightly smaller and carried fewer "ID tags" (specific proteins) on their surface.

• Analogy: Imagine a busy post office. The healthy moms send out a steady stream of standard-sized packages. The moms with asthma send out a massive flood of tiny, lightweight parcels. They are still packages, but they look and feel different.

2. The "Lung Cells" Reacted Differently Based on Who They Were

This is the most interesting part. The effect of the milk depended on who was receiving it.

• Scenario A: Healthy Lung Cells + Asthma Mom's Milk

  • Result: The healthy lung cells calmed down.
  • What happened: The asthma mom's milk actually reduced the release of "angry" chemicals (inflammatory cytokines) like MCP-1 and IL-6.
  • Analogy: It's like a fire alarm going off in a healthy house, but the milk from the asthma mom handed the fire department a "Do Not Disturb" sign, and the fire (inflammation) died down.

• Scenario B: Asthma Lung Cells + Asthma Mom's Milk

  • Result: The asthma lung cells got a bit more "helpful" but also a bit more "active."
  • What happened: The milk increased the release of "peacekeeper" chemicals (anti-inflammatory) like IL-10 and IL-1Ra, which try to soothe the lungs. However, it also bumped up a specific chemical (IL-2) that can sometimes be tricky.
  • Analogy: The asthma lung cells were already stressed out. The milk from the asthma mom tried to hand them a "calm down" blanket (peacekeepers), but also handed them a "get moving" pep talk (IL-2). It was a complex mix of trying to fix the problem while acknowledging the stress.

3. No Harm Done

The scientists checked to make sure the milk didn't kill the lung cells. It didn't. The cells were happy and healthy after the treatment.

---

Why Does This Matter?

For a long time, we thought breastfeeding was just about nutrition and fighting tummy bugs. This study suggests that breast milk is also a communication tool for the lungs.

• The Takeaway: Even if a mother has asthma, her breast milk isn't "bad" for the baby. In fact, her milk might contain special "drones" that are uniquely adapted to help manage inflammation.
• The Twist: The milk from an asthmatic mom seems to know how to talk to lung cells differently. It might be trying to teach the baby's lungs how to handle the specific challenges of an asthmatic environment.

The Bottom Line

Think of breast milk as a personalized medicine kit sent from mother to child. If the mother has asthma, the kit changes its contents slightly. It sends out more, smaller packages with different instructions. When these packages land on the baby's lungs, they seem to have a soothing effect, potentially helping to prevent the lungs from becoming too inflamed.

This research opens a door to understanding how breastfeeding protects babies from asthma, suggesting that the milk itself is a powerful, active participant in building a healthy respiratory system.

Technical Summary

1. Problem Statement

Breastfeeding is widely recognized as protective against respiratory infections and potentially asthma development in infants, yet the precise molecular mechanisms remain unclear. While breast milk contains bioactive extracellular vesicles (EVs) capable of immunomodulation, it is unknown whether the maternal asthma status alters the biophysical and biochemical composition of these EVs. Furthermore, the specific impact of these maternal EVs on human airway smooth muscle (hASM) cells—a key driver of airway remodeling and inflammation in asthma—has not been investigated. The study addresses whether maternal asthma changes breast milk EV (BM-EV) cargo and if these altered EVs exert differential immunomodulatory effects on hASM cells depending on the recipient's asthma status.

2. Methodology

Study Cohort and Sample Collection:

• Participants: Breast milk samples were collected from 10 Caucasian mothers (5 with asthma, 5 without) at 12–15 weeks postpartum from the Canadian Healthy Infant Longitudinal Development (CHILD) Cohort.
• Matching: Donors were matched by age, BMI, race, and lactation stage. Mothers with other chronic conditions (e.g., diabetes) were excluded.

EV Isolation and Characterization:

• Isolation: Breast milk was processed to remove fat and cellular debris, followed by isolation of EVs using Size Exclusion Chromatography (SEC) (qEV columns). Fractions F7–9 were identified as enriched in small EVs (sEVs) and low in lipoproteins.
• Biophysical Analysis:
  • Morphology: Transmission Electron Microscopy (TEM) confirmed spherical, intact vesicles (~100 nm).
  • Size & Concentration: Tunable Resistive Pulse Sensing (TRPS) was used to measure particle size distribution, concentration, and zeta potential.
  • Protein Quantification: MicroBCA assays determined total protein yield.
• Biochemical Profiling: Western blotting assessed the expression of EV markers (CD63, CD9, CD81, TSG101, Flotillin-1, HSP70) and negative controls (ApoA1 for lipoproteins, MMP2/ARF6 for microvesicles).

Functional Assays (Cell Culture):

• Recipient Cells: Primary human airway smooth muscle (hASM) cells were obtained from two donors: one non-asthmatic (control) and one asthmatic. Cells were hTERT-immortalized to allow for stable culture.
• Treatment: hASM cells were co-cultured with BM-EVs from asthmatic or control mothers for 48 hours. Some experiments included a pre-challenge with IL-1β (10 ng/ml) to simulate inflammatory conditions.
• Uptake Verification: EVs were labeled with PKH67 dye and confirmed to be internalized by hASM cells via confocal microscopy.
• Viability: MTT assays confirmed that EV treatment did not affect cell viability.
• Cytokine Analysis: Multiplex assays (Human Focused 15-Plex) quantified the release of 15 inflammatory mediators (e.g., MCP-1, IL-6, IL-10, IL-2, IL-1Ra) in the conditioned media.

3. Key Contributions

• First characterization of BM-EVs based on maternal asthma: The study establishes that maternal asthma status significantly alters the biophysical properties and protein cargo of breast milk EVs.
• Recipient-Cell Specificity: It demonstrates that the immunomodulatory effect of BM-EVs is not uniform; it depends on the interaction between the donor's asthma status and the recipient cell's asthma status.
• Mechanistic Insight into Breastfeeding: It provides evidence that BM-EVs can directly modulate airway smooth muscle inflammation, suggesting a potential mechanism for how breastfeeding influences infant respiratory health.

4. Key Results

Biophysical and Biochemical Differences:

• Size & Concentration: Asthmatic BM-EVs were slightly smaller (135.6 nm vs. 148.3 nm, p=0.06) but had a ~5-fold higher concentration of total and small EVs (<200 nm) compared to controls (p < 0.01).
• Stability: Zeta potential (stability) was unchanged between groups (~ -12 mV).
• Protein Cargo: Asthmatic BM-EVs showed significantly reduced expression of key small EV markers compared to controls:
  • CD63: ~86% reduction (p=0.022).
  • Flotillin-1: ~40% reduction (p=0.020).
  • HSP70: ~69% reduction (p=0.087).
  • CD9: ~24% reduction (p=0.065).
  • Note: Total protein yield per vesicle remained unchanged, suggesting the cargo composition, not quantity, is altered.

Functional Effects on hASM Cells:
The effects of asthmatic BM-EVs were highly dependent on the recipient cell type:

• In Non-Asthmatic hASM Cells: Asthmatic BM-EVs exerted an anti-inflammatory effect, significantly reducing the release of pro-inflammatory cytokines:
  • MCP-1: ↓55% (p=0.029).
  • IL-6: ↓45% (p=0.080).
  • IL-2: ↓32% (p=0.097).
• In Asthmatic hASM Cells: Asthmatic BM-EVs exerted a pro-inflammatory/immunomodulatory shift, increasing the release of:
  • Anti-inflammatory IL-10: ↑32% (p=0.066).
  • Anti-inflammatory IL-1Ra: ↑75% (p=0.088).
  • Pro-inflammatory IL-2: ↑57% (p=0.069).
• IL-1β Challenge: When cells were pre-stimulated with IL-1β, BM-EVs generally failed to modulate cytokine release, except for a slight increase in IL-4 in non-asthmatic cells treated with asthmatic EVs.

5. Significance and Conclusion

This study reveals that maternal asthma alters the "quality" of breast milk EVs, resulting in a distinct population of smaller, more numerous vesicles with reduced expression of specific tetraspanins and chaperone proteins. Crucially, these altered EVs do not act uniformly; they modulate airway smooth muscle inflammation in a recipient-cell specific manner.

• Protective Mechanism: The reduction of pro-inflammatory cytokines in non-asthmatic cells suggests a potential protective mechanism where breast milk from asthmatic mothers might help "prime" or protect the infant's airways against inflammation.
• Complexity of Asthma: The increase in IL-2 and IL-10 in asthmatic cells suggests a complex feedback loop where the infant's own asthmatic airway environment interacts differently with maternal EVs.
• Future Directions: The findings highlight the need to investigate the specific cargo (miRNA, proteins) responsible for these effects and to explore how these EVs reach the infant's airways (via aerosolization during suckling) to influence lung development and asthma pathogenesis.

Limitations: The study utilized a small sample size (N=5/group), used mature milk (13-15 weeks) rather than colostrum, and focused solely on hASM cells, excluding other lung cell types like epithelial or immune cells. Despite this, the study provides a robust foundation for understanding the interplay between maternal health, breast milk EVs, and infant respiratory immunity.